{"slug":"tesamorelin-tirzepatide","verification":{"valid":true,"entries":2,"head":"5b42037a86624caf4bc6c4027bd566fcad876c2d260a860752d051f74e61e26e"},"energy":{"passes":2,"tokens_in":34352,"tokens_out":4162,"tokens_total":38514,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"5b42037a86624caf4bc6c4027bd566fcad876c2d260a860752d051f74e61e26e"},"provenance":[{"ts":"2026-06-29T23:12:09.059Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Tesamorelin for Tirzepatide\nSlug: tesamorelin-tirzepatide\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"dual_compound\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"tirzepatide\",\"name\":\"Tirzepatide\"},{\"id\":\"tesamorelin\",\"name\":\"Tesamorelin\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"tirzepatide\",\"name\":\"Tirzepatide\",\"section_title\":\"Why Tirzepatide might help you\",\"layer\":\"metabolic load / body weight\",\"steps\":[\"**What keeps failing:** Same mechanical overload pattern as other GLP-1 contexts at higher body weight.\",\"**What Tirzepatide is studied to do:** Studied for GLP-1/GIP weight loss — load reduction on spine and joints.\",\"**Therefore for you:** If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"],\"prose\":\"1. **What keeps failing:** Same mechanical overload pattern as other GLP-1 contexts at higher body weight.\\n2. **What Tirzepatide is studied to do:** Studied for GLP-1/GIP weight loss — load reduction on spine and joints.\\n3. **Therefore for you:** If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"},{\"peptide\":\"tesamorelin\",\"name\":\"Tesamorelin\",\"section_","response":"{\n  \"slug\": \"tesamorelin-tirzepatide\",\n  \"title\": \"Tesamorelin and Tirzepatide: Layered Evidence on Metabolic Load and Visceral Fat Pathways\",\n  \"body\": \"## What's breaking down\\n\\nWhen body weight stays elevated, compressive forces on the lumbar spine increase roughly 4 pounds for every extra pound carried. This mechanical overload pattern contributes to ongoing tissue stress. Tirzepatide use often produces substantial total weight reduction, which can ease that load, yet visceral adipose tissue around organs may persist or shift independently. Excess visceral fat links to altered metabolic signaling and GH axis dynamics. If these layers continue unchecked, breakdown outpaces repair, sustaining the original imbalance even as overall scale weight drops.\\n\\n## Why Tirzepatide might help you\\n\\n1. What keeps failing: The same mechanical overload pattern appears in higher body weight states, where each pound adds compressive force to the spine and joints.\\n2. What Tirzepatide is studied to do: Human trials examined GLP-1/GIP receptor agonism for weight loss, with documented reductions in total body mass that lower overall mechanical demands.\\n3. Therefore for you: If the metabolic load and body weight layer forms part of your situation, Tirzepatide is discussed because it targets reduction of that load, supporting repair through decreased mechanical stress rather than symptom masking.\\n\\nHuman trial data show mean weight reductions of 15.0% to 20.9% at 72 weeks across 5 mg, 10 mg, and 15 mg doses versus 3.1% with placebo (human|source s1). A separate 88-week withdrawal trial reported 25.3% total reduction when continued versus 9.9% with placebo after lead-in (human|source s2). Meta-analysis of ten RCTs confirmed average losses of 9.81 kg versus placebo or comparators (human|source s3).\\n\\n## Why Tesamorelin might help you\\n\\n1. What keeps failing: Visceral fat accumulation can sustain altered GH axis signaling and metabolic strain independent of total body weight.\\n2. ","tokens_in":34352,"tokens_out":4162,"cost":0,"prev":"genesis","hash":"c4546e2fc1ab0a9867144c6a95d7bef6e49ec2488d6485b7aaadd14fa7b9d195"},{"ts":"2026-07-17T02:42:28.420Z","model":"owner","action":"voxel_divide","prompt":"","input":"tesamorelin-tirzepatide","response":"24 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"c4546e2fc1ab0a9867144c6a95d7bef6e49ec2488d6485b7aaadd14fa7b9d195","hash":"5b42037a86624caf4bc6c4027bd566fcad876c2d260a860752d051f74e61e26e"}]}